STAB (Statera BioPharma) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Statera BioPharma Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Statera BioPharma  (OTCPK:STAB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Statera BioPharma Cyclically Adjusted PB Ratio Related Terms


Statera BioPharma Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Cyclically Adjusted PB Ratio Chart

Statera BioPharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.39

Statera BioPharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 1.24 0.20 0.21 0.11

STAB vs NRBO, PALI, BLCM: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Statera BioPharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Statera BioPharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Cyclically Adjusted PB Ratio falls into.



Statera BioPharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Statera BioPharma's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, Statera BioPharma's adjusted Book Value per Share data for the three months ended in Sep. 2022 was:

Adj_Book=Book Value per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-0.2/296.8080*296.8080
=-0.200

Current CPI (Sep. 2022) = 296.8080.

Statera BioPharma Quarterly Data

Book Value per Share CPI Adj_Book
201212 9.160 229.601 11.841
201303 4.424 232.773 5.641
201306 2.802 233.504 3.562
201309 1.033 234.149 1.309
201312 0.700 233.049 0.892
201403 1.566 236.293 1.967
201406 2.258 238.343 2.812
201409 1.163 238.031 1.450
201412 0.625 234.812 0.790
201503 -0.410 236.119 -0.515
201506 -1.387 238.638 -1.725
201509 1.354 237.945 1.689
201512 1.369 236.525 1.718
201603 1.361 238.132 1.696
201606 1.191 241.018 1.467
201609 1.296 241.428 1.593
201612 1.169 241.432 1.437
201703 1.024 243.801 1.247
201706 0.875 244.955 1.060
201709 0.762 246.819 0.916
201712 0.657 246.524 0.791
201803 0.550 249.554 0.654
201806 0.466 251.989 0.549
201809 0.363 252.439 0.427
201812 0.320 251.233 0.378
201903 0.244 254.202 0.285
201906 0.190 256.143 0.220
201909 0.147 256.759 0.170
201912 0.087 256.974 0.100
202003 0.068 258.115 0.078
202006 0.255 257.797 0.294
202009 0.211 260.280 0.241
202012 -0.273 260.474 -0.311
202103 0.917 264.877 1.028
202106 0.875 271.696 0.956
202109 2.312 274.310 2.502
202112 -0.042 278.802 -0.045
202203 -0.049 287.504 -0.051
202206 -0.139 296.311 -0.139
202209 -0.200 296.808 -0.200

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.